Literature DB >> 16441235

Targeting the PTPome in human disease.

Lutz Tautz1, Maurizio Pellecchia, Tomas Mustelin.   

Abstract

Protein tyrosine phosphatases (PTPs) play vital roles in numerous cellular processes and are implicated in a growing number of human diseases, ranging from cancer to cardiovascular, immunological, infectious, neurological and metabolic diseases. There are at least 107 genes in the human genome, collectively referred to as the human 'PTPome'. Here the authors review the involvement of PTPs in human disease, discuss their potential as drug targets, and current efforts to develop PTP inhibitors for the treatment of human disease. Finally, the authors present their view of the future for PTPs as drug targets.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16441235     DOI: 10.1517/14728222.10.1.157

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  41 in total

1.  NMR-based design and evaluation of novel bidentate inhibitors of the protein tyrosine phosphatase YopH.

Authors:  Marilisa Leone; Elisa Barile; Jesus Vazquez; Angel Mei; Donald Guiney; Russel Dahl; Maurizio Pellecchia
Journal:  Chem Biol Drug Des       Date:  2010-04-28       Impact factor: 2.817

2.  Inhibition of hematopoietic protein tyrosine phosphatase augments and prolongs ERK1/2 and p38 activation.

Authors:  Eduard Sergienko; Jian Xu; Wallace H Liu; Russell Dahl; David A Critton; Ying Su; Brock T Brown; Xochella Chan; Li Yang; Ekaterina V Bobkova; Stefan Vasile; Hongbin Yuan; Justin Rascon; Sharon Colayco; Shyama Sidique; Nicholas D P Cosford; Thomas D Y Chung; Tomas Mustelin; Rebecca Page; Paul J Lombroso; Lutz Tautz
Journal:  ACS Chem Biol       Date:  2011-11-17       Impact factor: 5.100

3.  Visualizing active-site dynamics in single crystals of HePTP: opening of the WPD loop involves coordinated movement of the E loop.

Authors:  David A Critton; Lutz Tautz; Rebecca Page
Journal:  J Mol Biol       Date:  2010-11-19       Impact factor: 5.469

Review 4.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

Review 5.  Generation of inhibitor-sensitive protein tyrosine phosphatases via active-site mutations.

Authors:  Anthony C Bishop; Xin-Yu Zhang; Anna Mari Lone
Journal:  Methods       Date:  2007-07       Impact factor: 3.608

6.  Development of molecular probes for second-site screening and design of protein tyrosine phosphatase inhibitors.

Authors:  Jesus Vazquez; Lutz Tautz; Jennifer J Ryan; Kristiina Vuori; Tomas Mustelin; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2007-03-30       Impact factor: 7.446

7.  Identification of novel, less toxic PTP-LAR inhibitors using in silico strategies: pharmacophore modeling, SADMET-based virtual screening and docking.

Authors:  Dara Ajay; M Elizabeth Sobhia
Journal:  J Mol Model       Date:  2011-04-27       Impact factor: 1.810

8.  In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation.

Authors:  Shuangding Wu; Massimo Bottini; Robert C Rickert; Tomas Mustelin; Lutz Tautz
Journal:  ChemMedChem       Date:  2009-03       Impact factor: 3.466

Review 9.  Is Cdc25 a druggable target?

Authors:  John S Lazo; Peter Wipf
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

10.  High-resolution crystal structures of the D1 and D2 domains of protein tyrosine phosphatase epsilon for structure-based drug design.

Authors:  George T Lountos; Sreejith Raran-Kurussi; Bryan M Zhao; Beverly K Dyas; Terrence R Burke; Robert G Ulrich; David S Waugh
Journal:  Acta Crystallogr D Struct Biol       Date:  2018-10-02       Impact factor: 7.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.